Evasion of targeted cancer therapy through stem-cell-like reprogramming
Prostate cancer variants expressing alternative lineage markers appear at relapse from antiandrogen therapy. We show that loss of the retinoblastoma (RB1) and tumor protein 53 (TP53) genes drives expression of stem cell reprogramming factors, lineage plasticity, and antiandrogen resistance. Epigenet...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2017-03-01
|
| Series: | Molecular & Cellular Oncology |
| Subjects: | |
| Online Access: | http://dx.doi.org/10.1080/23723556.2017.1291397 |
| _version_ | 1797677218579611648 |
|---|---|
| author | Kristine M. Wadosky Leigh Ellis David W. Goodrich |
| author_facet | Kristine M. Wadosky Leigh Ellis David W. Goodrich |
| author_sort | Kristine M. Wadosky |
| collection | DOAJ |
| description | Prostate cancer variants expressing alternative lineage markers appear at relapse from antiandrogen therapy. We show that loss of the retinoblastoma (RB1) and tumor protein 53 (TP53) genes drives expression of stem cell reprogramming factors, lineage plasticity, and antiandrogen resistance. Epigenetic manipulation restores antiandrogen sensitivity—suggesting an approach for treating lethal prostate cancers. |
| first_indexed | 2024-03-11T22:40:48Z |
| format | Article |
| id | doaj.art-7c803a2f071342e5b8cb8ba9a54beeb7 |
| institution | Directory Open Access Journal |
| issn | 2372-3556 |
| language | English |
| last_indexed | 2024-03-11T22:40:48Z |
| publishDate | 2017-03-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Molecular & Cellular Oncology |
| spelling | doaj.art-7c803a2f071342e5b8cb8ba9a54beeb72023-09-22T09:10:58ZengTaylor & Francis GroupMolecular & Cellular Oncology2372-35562017-03-014210.1080/23723556.2017.12913971291397Evasion of targeted cancer therapy through stem-cell-like reprogrammingKristine M. Wadosky0Leigh Ellis1David W. Goodrich2Roswell Park Cancer InstituteHarvard Medical School, Brigham and Women's Hospital, Dana-Farber Cancer InstituteRoswell Park Cancer InstituteProstate cancer variants expressing alternative lineage markers appear at relapse from antiandrogen therapy. We show that loss of the retinoblastoma (RB1) and tumor protein 53 (TP53) genes drives expression of stem cell reprogramming factors, lineage plasticity, and antiandrogen resistance. Epigenetic manipulation restores antiandrogen sensitivity—suggesting an approach for treating lethal prostate cancers.http://dx.doi.org/10.1080/23723556.2017.1291397epigenetic reprogrammingmouse modelsprostate cancertherapeutic resistancetumor suppressor genes |
| spellingShingle | Kristine M. Wadosky Leigh Ellis David W. Goodrich Evasion of targeted cancer therapy through stem-cell-like reprogramming Molecular & Cellular Oncology epigenetic reprogramming mouse models prostate cancer therapeutic resistance tumor suppressor genes |
| title | Evasion of targeted cancer therapy through stem-cell-like reprogramming |
| title_full | Evasion of targeted cancer therapy through stem-cell-like reprogramming |
| title_fullStr | Evasion of targeted cancer therapy through stem-cell-like reprogramming |
| title_full_unstemmed | Evasion of targeted cancer therapy through stem-cell-like reprogramming |
| title_short | Evasion of targeted cancer therapy through stem-cell-like reprogramming |
| title_sort | evasion of targeted cancer therapy through stem cell like reprogramming |
| topic | epigenetic reprogramming mouse models prostate cancer therapeutic resistance tumor suppressor genes |
| url | http://dx.doi.org/10.1080/23723556.2017.1291397 |
| work_keys_str_mv | AT kristinemwadosky evasionoftargetedcancertherapythroughstemcelllikereprogramming AT leighellis evasionoftargetedcancertherapythroughstemcelllikereprogramming AT davidwgoodrich evasionoftargetedcancertherapythroughstemcelllikereprogramming |